Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development
AbstractIntracranial malignancies, such as primary brain cancers and brain-localized metastases derived from peripheral cancers, are particularly difficult to treat with therapeutic agents, because the blood-brain barrier (BBB) effectively minimizes brain entry of the vast majority of agents arriving from the systemic circulation. Intranasal administration of cancer drugs has the potential to reach the brain via direct nose-to-brain transport, thereby circumventing the obstacle posed by the BBB. However, in the field of cancer therapy, there is a paucity of studies reporting positive results with this type of approach. A remarkable exception is the natural compound perillyl alcohol (POH). Its potent anticancer activity was convincingly established in preclinical studies, but it nonetheless failed in subsequent clinical trials, where it was given orally and displayed hard-to-tolerate gastrointestinal side effects. Intriguingly, when switched to intranasal delivery, POH yielded highly promising activity in recurrent glioma patients and was well tolerated. As of 2018, POH is the only intranasally delivered compound in the field of cancer therapy (outside of cancer pain) that has advanced to active clinical trials. In the following, we will introduce this compound, summarize its molecular mechanisms of action, and present the latest data on its clinical evaluation as an intranasally administered agent for glioma. View Full-Text
Share & Cite This Article
Chen, T.C.; Da Fonseca, C.O.; Schönthal, A.H. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. Int. J. Mol. Sci. 2018, 19, 3905.
Chen TC, Da Fonseca CO, Schönthal AH. Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development. International Journal of Molecular Sciences. 2018; 19(12):3905.Chicago/Turabian Style
Chen, Thomas C.; Da Fonseca, Clovis O.; Schönthal, Axel H. 2018. "Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development." Int. J. Mol. Sci. 19, no. 12: 3905.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.